Literature DB >> 28547588

Neurocognition in individuals with incidentally-identified meningioma.

Alissa M Butts1, Stephen Weigand2, Paul D Brown3, Ronald C Petersen4, Clifford R Jack5, Mary M Machulda6, Jane H Cerhan6.   

Abstract

Meningiomas are primary intracranial tumors that are often asymptomatic. To our knowledge, no study has attempted to describe neurocognitive function in patients with incidentally-discovered meningioma. We utilized the Mayo Clinic Study of Aging (MCSA), which is a population-based sample of Olmsted County, Minnesota residents that includes neuropsychological testing and brain MRI approximately every 15 months. Using a text search of radiologists' notes of 2402 MCSA individuals (mean age 77 years, scanned between 2004 and 2014) we identified 48 eligible subjects (2%) who had at least one meningioma. Most meningiomas were small (90% <3 cm). We matched each of the 48 subjects to 5 non-demented MCSA controls (n = 240) on age, sex, and education. Cognitive domains assessed included memory, attention-executive function, language, and visuospatial. More women (67%) had a meningioma than men (33%). Groups did not differ on prevalence of Mild Cognitive Impairment (Meningioma = 19%, Controls = 13%). Across cognitive domains, we observed similar performance for the two groups (p's ≥ 0.21). Subtle differences emerged in memory and language domains (p = 0.05 and p = 0.11) when we divided the Meningioma group by tumor location, wherein the small group with an infratentorial tumor performed more poorly than controls globally as well as on select memory and language measures. Our findings suggest that small meningiomas are generally cognitively benign, but that may change as the tumor evolves, and might be impacted by other factors such as meningioma location.

Entities:  

Keywords:  Brain tumor; Cognition; Meningioma; Neurocognitive

Mesh:

Substances:

Year:  2017        PMID: 28547588      PMCID: PMC5544551          DOI: 10.1007/s11060-017-2495-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordonna Fulop; Max Liu; Rachel Blanda; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2015-10-27       Impact factor: 12.300

2.  Risk factors for meningioma in postmenopausal women: results from the Iowa Women's Health Study.

Authors:  Derek R Johnson; Janet E Olson; Robert A Vierkant; Julie E Hammack; Alice H Wang; Aaron R Folsom; Beth A Virnig; James R Cerhan
Journal:  Neuro Oncol       Date:  2011-07-12       Impact factor: 12.300

3.  Incidental findings on brain MRI in the general population.

Authors:  Meike W Vernooij; M Arfan Ikram; Hervé L Tanghe; Arnaud J P E Vincent; Albert Hofman; Gabriel P Krestin; Wiro J Niessen; Monique M B Breteler; Aad van der Lugt
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

4.  Mayo's older Americans normative studies: category fluency norms.

Authors:  J A Lucas; R J Ivnik; G E Smith; D L Bohac; E G Tangalos; N R Graff-Radford; R C Petersen
Journal:  J Clin Exp Neuropsychol       Date:  1998-04       Impact factor: 2.475

5.  Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients.

Authors:  David van Nieuwenhuizen; Martin Klein; Lukas J A Stalpers; Sieger Leenstra; Jan J Heimans; Jaap C Reijneveld
Journal:  J Neurooncol       Date:  2007-04-13       Impact factor: 4.130

6.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2014-09-04       Impact factor: 44.182

7.  Late neurocognitive sequelae in patients with WHO grade I meningioma.

Authors:  M Dijkstra; D van Nieuwenhuizen; L J A Stalpers; M Wumkes; M Waagemans; W P Vandertop; J J Heimans; S Leenstra; C M Dirven; J C Reijneveld; M Klein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-07-24       Impact factor: 10.154

8.  Neurocognitive functioning and health-related quality of life in patients with radiologically suspected meningiomas.

Authors:  D van Nieuwenhuizen; N Ambachtsheer; J J Heimans; J C Reijneveld; S M Peerdeman; M Klein
Journal:  J Neurooncol       Date:  2013-05-03       Impact factor: 4.130

9.  Neuropsychological outcome after fractionated stereotactic radiotherapy (FSRT) for base of skull meningiomas: a prospective 1-year follow-up.

Authors:  Sarah Steinvorth; Grit Welzel; Martin Fuss; Jürgen Debus; Susanne Wildermuth; Michael Wannenmacher; Frederik Wenz
Journal:  Radiother Oncol       Date:  2003-11       Impact factor: 6.280

10.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

View more
  8 in total

1.  Factors Associated With Meningioma Detected in a Population-Based Sample.

Authors:  Jane H Cerhan; Alissa M Butts; Jeremy A Syrjanen; Jeremiah A Aakre; Paul D Brown; Ronald C Petersen; Clifford R Jack; Rosebud O Roberts
Journal:  Mayo Clin Proc       Date:  2019-02       Impact factor: 7.616

2.  Patient-reported outcome and cognitive measures to be used in vascular and brain tumor surgery: proposal for a minimum set.

Authors:  Silvia Schiavolin; Arianna Mariniello; Morgan Broggi; Giorgia Abete-Fornara; Alessandra Bollani; Giulio Palmas G; Gabriella Bottini; Matteo Querzola; Pina Scarpa; Alessandra Casarotti; Sara De Michele; Valeria Isella; Ilaria Mauri; Alessandra Maietti; Valentina Miramonti; Maria Immacolata Orru; Marta Pertichetti; Elisa Pini; Rossana Regazzoni; Sara Subacchi; Paolo Ferroli; Matilde Leonardi
Journal:  Neurol Sci       Date:  2022-06-02       Impact factor: 3.830

3.  A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas.

Authors:  Abdurrahman I Islim; Ruwanthi Kolamunnage-Dona; Midhun Mohan; Richard D C Moon; Anna Crofton; Brian J Haylock; Nitika Rathi; Andrew R Brodbelt; Samantha J Mills; Michael D Jenkinson
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

4.  Psychological Burden in Meningioma Patients under a Wait-and-Watch Strategy and after Complete Resection Is High-Results of a Prospective Single Center Study.

Authors:  Darius Kalasauskas; Naureen Keric; Salman Abu Ajaj; Leoni von Cube; Florian Ringel; Mirjam Renovanz
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

5.  Comparative Analysis of the MRI Characteristics of Meningiomas According to the 2016 WHO Pathological Classification.

Authors:  Juan Yu; Fan-Fan Chen; Han-Wen Zhang; Hong Zhang; Si-Ping Luo; Guo-Dong Huang; Fan Lin; Yi Lei; Liangping Luo
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

6.  A Large Cavernous Sinus Giant Cell Tumor Invading Clivus and Sphenoid Sinus Masquerading as Meningioma: A Case Report and Literature Review.

Authors:  Shasha Hu; Shaowen Cheng; Yu Wu; Yanyan Wang; XinNian Li; Jiaxuan Zheng; Jiao Li; Lei Peng; Jian Yang
Journal:  Front Surg       Date:  2022-03-24

7.  A prospective study of the natural history of incidental meningioma-Hold your horses!

Authors:  Maziar Behbahani; Geir Olve Skeie; Geir Egil Eide; Annbjørg Hausken; Morten Lund-Johansen; Bente Sandvei Skeie
Journal:  Neurooncol Pract       Date:  2019-04-17

8.  Clinical and Biological Correlates of Preoperative Cognitive Functioning of Glioma and Meningioma Patients.

Authors:  Aiste Pranckeviciene; Vytenis P Deltuva; Arimantas Tamasauskas; Jurate Zegliene; Adomas Bunevicius
Journal:  Biomed Res Int       Date:  2020-05-08       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.